Exclusive: En route to first xenotransplantation trial, eGenesis taps new CEO weeks after CMO hire
When Michael Curtis joined xenotransplantation startup eGenesis as president of R&D in late-2020, he knew he’d one day become CEO.
He and Paul Sekhri, the outgoing CEO who will remain on the board of the Church lab spinout and serve as senior advisor, have spent the past 18 months mapping out that transition. He climbs the ladder just two weeks after eGenesis hired former transplant surgeon and two-decade clinical development leader Eliezer Katz as medical chief.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.